EUDA Health Slashes Warrant Price to $4 and Pursues Stem Cell JV

Introduction

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based health technology company founded in 2022. It operates a digital healthcare ecosystem in Southeast Asia that utilizes an AI-driven platform to assess patients’ medical histories, triage conditions, connect users with clinicians, and predict treatment outcomes. EUDA targets the preventive healthcare market, focusing on the longevity sector across Southeast Asia and China, where a significant portion of the population is aging.

Corporate Structure

Headquartered in Singapore, EUDA employs between 51 and 200 staff as of December 2025. The company is organized into two reportable segments. The holistic wellness segment offers consumer products and services, including Bioenergy Capsules, stem cell therapies, and CRISPR-based gene editing, aimed at enhancing immunity and promoting cellular recovery. The property management segment provides management and security services for residential apartments, condominiums, office buildings, and shopping malls, generating a substantial portion of group revenue.

Digital healthcare by Luke Chesser

Recent Developments

On December 16, 2025, EUDA amended the terms of a warrant issued to Streeterville Capital LLC. The warrant, originally exercisable into 2,000,000 ordinary shares at $6.00 per share, had its exercise price reduced to $4.00. The minimum closing price threshold for a forced exercise was lowered from $7.50 to $6.00. If fully exercised, the company would realize approximately $8.02 million in net proceeds, of which $4.4 million is designated for marketing expenses, with the remainder for general corporate purposes and potential acquisitions. A new prospectus supplement reflecting these changes is expected to be filed as part of EUDA’s Form F-3 registration statement.

In December 2025, CEO Kelvin Chen indicated preliminary discussions with Guangdong Cell Biotech Co. Ltd., which specializes in stem cell therapies, to establish a joint venture for the distribution of regenerative treatments in Southeast Asia. This initiative aims to integrate EUDA’s digital platform with Guangdong Cell Biotech’s network of 37 treatment facilities in China, Indonesia, and Cambodia, potentially enhancing the company’s healthcare offerings and strengthening its market presence in the region.

On December 22, 2025, EUDA filed Form 6-K to report a press release issued that day. Although the details of the release are pending in Exhibit 99.1, stakeholders can anticipate updates on strategic partnerships, financial guidance, or new service launches.

Financial and Strategic Analysis

As of December 23, 2025, EUDA’s share price was USD 1.8232, reflecting a 34.06% increase on the day, with a trading volume of 2,049,801 shares. Over the past 52 weeks, the stock traded between USD 1.03 and USD 4.90. Key trailing-twelve-month metrics include revenue of USD 5.16 million, a gross margin of 22.39%, and a net loss margin of 40.53%. The company has a debt-to-equity ratio of 56.34% and a market capitalization of approximately USD 68.8 million, based on 37.8 million shares outstanding.

The warrant amendment indicates a strategy to secure additional capital under more favorable conditions for potential investors. However, with the closing share price on December 18, 2025, at USD 2.65—below the revised USD 4.00 exercise price—the likelihood of immediate warrant exercise remains uncertain. Long-term prospects rely on EUDA’s ability to drive revenue growth through its digital healthcare services and strategic partnerships.

Market Position and Industry Context

EUDA operates at the intersection of digital health and longevity, addressing preventive care needs in markets with aging populations. Its proprietary AI platform enables comprehensive patient engagement across various health stages including wellness, urgent care, and aftercare. The inclusion of non-invasive therapies, such as bioenergy treatment sessions and CRISPR gene editing, positions EUDA to meet the demand for accessible healthcare solutions. Additionally, the property management segment provides a diversified revenue stream that can help mitigate volatility associated with early-stage healthcare ventures. As a small-cap issuer on NASDAQ, EUDA’s liquidity profile is moderate, with a 10-day average trading volume of 0.22 million shares and intraday bid-ask spreads indicative of investor interest.

TL;DR

EUDA amended its warrant on December 16, 2025—lowering the exercise price to USD 4.00—and plans a prospectus supplement under Form F-3. Discussions with Guangdong Cell Biotech aim to establish a joint venture for stem cell therapies in Southeast Asia. With a share price on December 23 of USD 1.82, full warrant exercise remains dependent on a sustained increase in share price. Stakeholders await the December 22 press release for further strategic and financial updates.